trustpilot Fantastic service
Great service with regard to both information…
logomysorgente

02  4948  5291

  • What is AURORA

    Aurora is a next-generation noninvasive prenatal test. AURORA is safe, reliable, quick
    and early

  • Safe

    Thanks to an easy maternal blood drawn, you avoid miscarriage risks associated to invasive methods such as amniocentesis or chorionic villus sampling

  • Reliable

    Sensitivity higher than 99,9% for detecting the trisomy 21, responsible for the Down syndrome

  • Early and quick

    icona svegliaThe early detection of chromosome abnormalities is foundamental:
    you can undergo AURORA from the 10th week of pregnancy

    icona documentoThe test is quick: results are available in 5-7 working days. AURORA has the lower percentage of null test of the market: 0,1%

  • Mother's serenity in three simple steps

    icotelefona

    BOOK THE TEST

    icoesami

    MAKE A PERIPHERAL BLOOD DRAW

    icoginecologo

    READ RESULTS

  • eng slide mobile01
  • eng 2 151126 banner Aurora mobile 01
  • eng 151126 banner Aurora mobile 02
  • eng 151126 banner Aurora mobile 03
  • eng slide mobile05
Eng cover cartoon
Eng cover venturetti

Latest news from the world of genetics


New criterion for analyzing the risk of prostate cancer

The authors of an international study developed a new criterion for measuring prostate cancer risk. The score is used to analyze the genetic factors that could lead to an aggressive form of the tumor. In this way it would be possible to optimize the treatments and act immediately aggressively, if necessary.

Prostate cancer is the most diagnosed type of male cancer in developed countries. It is estimated to cause over 300,000 deaths worldwide each year. The new cases are about 1 million every year. A real emergency, to be addressed accordingly also with specific genetic tests.

Screening to calculate the specific prostate antigen (PSA) facilitates early diagnosis. However, it is frequent that completely healthy people still present high levels of PSA. In addition, there is always the danger of overly aggressive treatments on people with a mild tumor. The best thing would then be to identify in advance who risks developing a severe form of prostate cancer.

The PRACTICAL consortium developed a specific genetic test for prostate cancer. Researchers have also developed a tool to measure the risk of developing the aggressive form of the tumor. In this way it would be easier to provide each patient with the right treatment for his condition.

The researchers analyzed over 200,000 genetic variants from 31,747 European men. They identified 54 variations related to a higher risk of cancer. They then incorporated them into an analysis of the age of the subjects and their lifestyle. They thus obtained a new criterion for data analysis, applied to 6,411 men.

According to the test performed, the genetic test and the analysis would give very reliable results. If confirmed, we would have a valuable tool to develop more effective and specific treatments.

Source: medicalxpress.com

Link social

Link social